# A Pharmacokinetic Study of TS-142 in Patients with Hepatic Impairment

> **NCT05624944** · PHASE1 · COMPLETED · sponsor: **Taisho Pharmaceutical Co., Ltd.** · enrollment: 84 (actual)

## Conditions studied

- Patients with Mild or Moderate Hepatic Impairment

## Interventions

- **DRUG:** TS-142 5 mg

## Key facts

- **NCT ID:** NCT05624944
- **Lead sponsor:** Taisho Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-26
- **Primary completion:** 2023-12-05
- **Final completion:** 2023-12-05
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2025-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05624944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05624944, "A Pharmacokinetic Study of TS-142 in Patients with Hepatic Impairment". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05624944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*